Press Release For Immediate Release

Glenmark Generics receives three ANDA approvals from the USFDA

- **This includes tentative approval for Eszopiclone, the generic version of Sepracor's Lunesta® which achieved annual sales of USD 760 million**

December 23, 2010: Glenmark Generics Inc., USA , the United States subsidiary of Glenmark Generics Ltd, today announced that they have been granted approval for three Abbreviated New Drug Applications (ANDA) by the United States Food and Drug Administration (U.S. FDA).

Final ANDA approvals were received for Indomethacin 25 mg and 50 mg capsules, USP and Sulfamethoxazole and Trimethoprim double and single strength tablets. These products are currently available and the Company has commenced shipping from their New Jersey facility. According to IMS Health, total sales achieved for the 12 month period ending September 2010 were USD 20 million and USD 31 million, respectively.

Indomethacin is classified as a non-steriodal antirheumatic and has been found effective in active stages of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis. Sulfamethoxazole and Trimethoprim tablets are indicated for urinary tract infections, acute otitis media, acute exacerbations of chronic bronchitis in adults, shigellosis, pneumocystis carinii pneumonia and traveler's diarrhea in adults.

Tentative ANDA approval was granted to Glenmark for Eszopiclone, the generic version of Sepracor's Lunesta® which achieved annual sales of USD 760 million for the 12 month period ending September 2010 according to IMS Health and is the second highest selling branded prescription medication in its class.

Earlier this year, Glenmark entered into a settlement and license agreement with Sepracor to resolve a United States patent infringement suit related to Glenmark's filing an ANDA for Eszopiclone with the U.S. FDA. Under the terms of this agreement, and upon approval and entry of a Consent Judgment and Order of Permanent Injunction by the United States District Court for the District of New Jersey, Glenmark would be permitted to launch its generic product on the later of November 30, 2013, which is two and one half months (2.5 months) prior to the expiry of Sepracor's United States Patent 6,444,673, or May 30, 2014 if Sepracor

obtains pediatric exclusivity for Lunesta®. The settlement and license agreement and Consent Judgment and Order also would permit Glenmark to launch its generic product earlier under certain circumstances. The court's approval of the proposed Consent Judgment and Order of Permanent Injunction would dismiss Sepracor's and Glenmark's respective claims and defenses without prejudice in the consolidated litigation currently pending against Glenmark and other defendants.

Glenmark is currently authorized to distribute 65 products in the United States. The Company currently has 40 ANDA's filed with the U.S. FDA pending approval and continues to rely on the strength of its internal pipeline projects as well as continuing to explore partnerships to augment the breadth of their existing portfolio.

About Glenmark Generics Limited.

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:

Jason D'Souza

Glenmark, Mumbai, India Tel: [+91 22] 40189919

Email : connect@glenmark-generics.com